Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976429 | Brachytherapy | 2016 | 8 Pages |
Abstract
IS BT using the “hybrid” applicator provides a dosimetric advantage for target volume and organs at risk in large-volume (>5Â cm) tumors and is, thereby, clinically feasible. However, the long-term curative effect and possible toxicity need further clinical observation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Zhong-Shan Liu, Jie Guo, Xia Lin, Hong-Yong Wang, Ling Qiu, Xiao-Jun Ren, Yun-Feng Li, Bing-Ya Zhang, Tie-Jun Wang,